Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dr Reddy's Rituximab Build-Up And Going Beyond The Pill

Executive Summary

Nine years after the launch of its biosimilar rituximab in India, Dr Reddy's Laboratories (DRL) claims a tenfold increase in the number of patients treated with the monoclonal antibody. M V Ramana, DRL's executive vice president and head branded markets (India and emerging countries) tells Scrip about his plans for the product in Russia and elsewhere and the firm's thrust on delivering care beyond the pill.

You may also be interested in...

Dr Reddy’s De Vré On Momentum In US Biosimilars Market, Interchangeability

The global head of Dr Reddy’s biologics business unit, Raymond De Vré, discusses in an interview with Scrip how things are looking up in the US biosimilars market, why interchangeability isn’t a major concern and how galloping volume growth is being seen by the company in emerging markets.

Dr Reddy's Slumps In Q1 But Will Pressures Ease Soon?

Dr. Reddy’s Laboratories (DRL) has reported a slump in profits for the first quarter, dented by a decline in volume growth and pricing pressure in the US as well as a loss of business in Venezuela. While the firm's long term story appears intact, resolution of compliance issues at its Indian sites and product flows in the US and other markets (DRL expects to participate in a Russian tender for rituximab) could lift investor sentiment significantly.

Another Rituximab Debuts In India But No Price Contest?

The privately owned Indian firm Hetero has launched rituximab, its biosimilar version of Roche's MabThera/Rituxan, in India, trailing a clutch of local peers onto the market, although it is not yet clear what price advantages it may have over rivals.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts